Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

Journal of Clinical Oncology

Volumn 34, Issue 14, 2016, Pages 1584-1593

  Bellet, Meritxell ^a,b,c,d   Gray, Kathryn P ^l,m,n   Francis, Prudence A ^s   Láng, István ^t   Ciruelos, Eva ^d,e   Lluch, Ana ^d,g   Climent, Miguel Angel ^d,h   Catalán, Gustavo ^d,i   Avella, Antoni ^d,j   Bohn, Uriel ^d,k   González Martin, Antonio ^d,f   Ferrer, Roser ^b   Catalán, Roberto ^b   Azaro, Analía ^a,b   Rajasekaran, Agnita ^q   Morales, Josefa ^d   Vázquez, Josep ^d   Fleming, Gini F ^r   Price, Karen N ^n,o   Regan, Meredith M ^l,n,p  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d SOLTI Group ^*  (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f MD ANDERSON CANCER CENTER   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

ⁱ HOSPITAL SON LLÀTZER   (Spain)

^j HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^k Hospital Dr Negrín de Gran Canaria ^*  (Spain)

^l Dana Farber Cancer Institute   (Spain)

^m HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ International Breast Cancer Study Group Statistical Center   (United States)

^o Frontier Science and Technology Research Foundation Inc   (United States)

^p HARVARD MEDICAL SCHOOL   (United States)

^q SYNEOS HEALTH   (United States)

^r UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^s UNIVERSITY OF MELBOURNE   (Australia)

^t NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRONE; ESTRONE SULFATE; EXEMESTANE; FOLLITROPIN; LUTEINIZING HORMONE; TAMOXIFEN; TRIPTORELIN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; EARLY CANCER; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GAS CHROMATOGRAPHY; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARIAN FUNCTION SUPPRESSION; OVARY FUNCTION; PATIENT HISTORY OF CHEMOTHERAPY; PREMENOPAUSE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BLOOD; BREAST NEOPLASMS; CONTROLLED STUDY; DRUG EFFECTS; OVARY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; OVARY; TAMOXIFEN; TRIPTORELIN PAMOATE;

EID: 84963756612     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.2259     Document Type: Article

References (47)

1. Beatson GW. On treatment of inoperable cases of carcinoma of themamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2:104-107, 162-165, 1896
2. Boccardo F, Rubagotti A, Perrotta A, et al: Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 5:337-342, 1994
3. Taylor CW, Green S, Dalton WS, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. J Clin Oncol 16: 994-999, 1998
4. Blamey RW, Jonat W, Kaufmann M, et al: Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 28A:810-814, 1992
5. Schmid P, UntchM, Kossé V, et al: Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: The TABLE study. J Clin Oncol 25:2509-2515, 2007
6. Jannuzzo MG, Di Salle E, Spinelli R, et al: Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat 113:491-499, 2009
7. Walker KJ, Walker RF, Turkes A, et al: Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. Eur J Cancer Clin Oncol 25:651-654, 1989
8. Klijn JG, Beex LV, Mauriac L, et al: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 92:903-911, 2000
9. Rossi E, Morabito A, De Maio E, et al: Endocrine effects of adjuvant letrozole+triptorelin compared with tamoxifen+triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 26: 264-270, 2008
10. Masuda N, Sagara Y, Kinoshita T, et al: Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): A double-blind, randomised phase 3 trial. Lancet Oncol 13:345-352, 2012
11. Celio L, Martinetti A, Ferrari L, et al: Premenopausal breast cancer patients treated with a gonadotropinreleasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. Anticancer Res 19:2261-2268, 1999
12. Forward DP, Cheung KL, Jackson L, et al: Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90: 590-594, 2004
13. Torrisi R, Bagnardi V, Pruneri G, et al: Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 97:802-808, 2007
14. Cheung KL, Agrawal A, Folkerd E, et al: Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer 46: 2936-2942, 2010
15. Carlson RW. Schurman CM, et al: Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 28: 3917-3921, 2010
16. Park IH, Ro J, Lee KS, et al: Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol 28: 2705-2711, 2010
17. Pagani O, Regan MM, Walley BA, et al: TEXT and SOFT Investigators; International Breast Cancer Study Group: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107-118, 2014
18. Francis PA, Regan MM, Fleming GF, et al: Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:1673, 2015
19. Soysal S, Soysal ME, Ozer S, et al: The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: A prospective randomized trial. Hum Reprod 19:160-167, 2004
20. Reichel RP, Schweppe KW; Zoladex Endometriosis Study Group: Goserelin (Zoladex) depot in the treatment of endometriosis. Fertil Steril 57: 1197-1202, 1992
21. Filicori M, Flamigni C, Cognigni G, et al: Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 77:130-133, 1993
22. Dowsett M, Stein RC, Coombes RC: Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 43: 155-159, 1992
23. Dowsett M, Doody D, Miall S, et al: Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 56: 25-34, 1999
24. Smith IE, Dowsett M, Yap YS, et al: Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol 24:2444-2447, 2006
25. Burstein HJ, Mayer E, Patridge AH, et al: Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: Cases and lessons. Clin Breast Cancer 7:158-161, 2006
26. Santen RJ, Demers L, Ohorodnik S, et al: Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72:666-671, 2007
27. Lee JS, Ettinger B, Stanczyk FZ, et al: Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 91:3791-3797, 2006
28. Hothorn T, Hornik K, van de Wiel MA, et al: A lego system for conditional inference. Am Stat 60: 257-263, 2006
29. Hothorn T, Hornik K, van de Wiel MA, et al: Implementing a class of permutation tests: The coin package. J Stat Softw 28:1-23, 2008
30. Hajek J, Sidak Z, Sen PK. Theory of Rank Tests. San Diego, CA, Academic Press, 1999
31. Folkerd EJ, Lønning PE, Dowsett M: Interpreting plasma estrogen levels in breast cancer: Caution needed. J Clin Oncol 32:1396-1400, 2014
32. Lønning PE, Geisler J, Krag LE, et al: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patientswith surgically resected early breast cancer. J Clin Oncol 23:5126-5137, 2005
33. Guerrero A, Gavilá J, Folkerd E, et al: Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol 24:674-679, 2013
34. Henry NL, Xia R, Banerjee M, et al: Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol 24:2011-2016, 2013
35. Geisler J, Haynes B, Anker G, et al: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20: 751-757, 2002
36. Dixon JM, Renshaw L, Young O, et al: Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26:1671-1676, 2008
37. Geisler J, Helle H, Ekse D, et al: Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 14:6330-6335, 2008
38. Ellis MJ, Suman VJ, Hoog J, et al: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 29:2342-2349, 2011
39. Rose C, Vtoraya O, Pluzanska A, et al: An open randomised trial of second-line endocrine therapy in advanced breast cancer: Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318-2327, 2003
40. Goss PE, Ingle JN, Pritchard KI, et al: Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27-A randomized controlled phase III trial. J Clin Oncol 31:1398-1404, 2013
41. Spinelli R, Januzzo MG, Pogessi I, et al: Pharmacokinetics (PK) of aromasin (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). Eur J Cancer 35: S295, 1999 (suppl 4)
42. Wang L, Ellsworth KA, Moon I, et al: Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 70:319-328, 2010
43. Lunardi G, Piccioli P, Bruzzi P, et al: Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. Breast Cancer Res Treat 137:167-174, 2013
44. Folkerd EJ, Dixon JM, Renshaw L, et al: Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 30:2977-2980, 2012
45. Sestak I, Distler W, Forbes JF, et al: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 28:3411-3415, 2010
46. Ewertz M, Gray KP, Regan MM, et al: Obesity and risk of recurrence or death after adjuvant endocrine therapywith letrozole or tamoxifen in the Breast International Group 1-98 trial. J Clin Oncol 30: 3967-3975, 2012
47. Pfeiler G, Königsberg R, Fesl C, et al: Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. J Clin Oncol 29:2653-2659, 2011